Mosunetuzumab
Transformed Follic Lymph to Diff Large B-Cell Lymphoma
SWOG Cancer Research Networkmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Transformed Follic Lymph to Diff Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tisagenlecleucel SWOG Cancer Research Network | Phase 2 | CCC |
Fludarabine SWOG Cancer Research Network | Phase 2 | CCC |
Cyclophosphamide SWOG Cancer Research Network | Phase 2 | CCC |
Jcar017 (Lisocabtagene Maraleucel) SWOG Cancer Research Network | Phase 2 | CCC |
Axicabtagene Ciloleucel SWOG Cancer Research Network | Phase 2 | CCC |
Polatuzumab Vedotin SWOG Cancer Research Network | Phase 2 | CCC |
Same molecule, other indications
Mosunetuzumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →